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ORIGINAL ARTICLE
Breast cancer-associated missense mutants of the PALB2 WD40
domain, which directly binds RAD51C, RAD51 and BRCA2,
disrupt DNA repair
J-Y Park1, TR Singh1, N Nassar1,2, F Zhang1, M Freund3, H Hanenberg3,4,5, AR Meetei1,2 and PR Andreassen1,2
Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an
increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as
Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2.
Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these
homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2
WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a
complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated
with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I
missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2–RAD51C–BRCA2
complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced
HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex,
RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2.
Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based
upon the PALB2 WD40 domain binding to RAD51C and BRCA2.
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INTRODUCTION
Inherited loss-of-function mutations in genes involved in the
maintenance of genomic stability are associated with an increased
cancer incidence in carriers of heterozygous mutations. BRCA1 and
BRCA2, the two most prominent tumor suppressor genes linked to
an inherited susceptibility to breast and ovarian cancer,1–3 encode
proteins that function in the homologous recombination (HR) DNA
repair pathway.4,5 BRCA2 regulates oligomerization of the RAD51
recombinase, which is necessary for it to form a nucleoprotein
ﬁlament with single-strand DNA.6,7
PALB2 and RAD51C are other DNA repair proteins linked
to breast and/or ovarian cancer.8–12 PALB2, the ‘partner and
localizer’ of BRCA2, interacts with both BRCA1 and BRCA2 through
its N-terminal coiled-coil and C-terminal WD40 domains,
respectively.12–16 Notably, the recruitment of BRCA2 to sites of
DNA damage and its function in HR critically depend on the
presence of a normal PALB2 protein.10,12,15,17
WD40 domains are ring-like b-propeller structures with seven
blades that mediate protein–protein interactions.18 Truncation or
frameshift mutants of PALB2 that perturb all, or a portion, of the
WD40 domain abrogate the association of PALB2 with BRCA2, the
assembly of RAD51 foci, and cellular resistance to DNA-
crosslinking agents such as mitomycin C.12,13,15 The
pathogenicity of these truncation mutants has generally been
attributed to disruption of the interaction of PALB2 with BRCA2,
but RAD51 also interacts with the WD40 domain of PALB2.19,20
Although missense mutants/variants of the PALB2 WD40 domain
have also been identiﬁed in breast cancer patients,21–31 their
effect on the function of the PALB2 protein in DNA-damage
responses, and therefore their pathogeneticity, is still largely
unknown.
RAD51C is one of ﬁve RAD51 paralogs that have been identiﬁed
in somatic mammalian cells, along with RAD51B, RAD51D, XRCC2
and XRCC3. These proteins are of a similar size as RAD51 but have
an overall low homology to RAD51 (20–30%).32 Like RAD51, each
of the paralogs is required for DNA repair by HR,33 but their
speciﬁc roles in HR are not well characterized and seem to be
distinct from the function of RAD51.
The RAD51 paralogs form at least two distinct protein
complexes in cells: a RAD51B–RAD51C–RAD51D–XRCC2 complex
and a RAD51C–XRCC3 complex. RAD51C is the only paralog
present in both.34 Aside of an apparent interaction with RAD18,35
other RAD51C interactors have not been identiﬁed.
Here, we demonstrate that RAD51C has a direct protein–protein
interaction with PALB2. In addition to their roles in breast/ovarian
cancer, FANCD1/BRCA2, FANCN/PALB2, and FANCO/RAD51C are
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among the 16 currently identiﬁed FA genes.36,37 The functional
relationship of RAD51C to other FA proteins, including PALB2, was
previously unknown. Our results suggest that the PALB2 WD40
domain may scaffold the RAD51C, RAD51 and BRCA2 HR proteins
into a complex. Selected missense mutations of the PALB2 WD40
domain, found in breast cancer patients,21 perturb this complex,
but to a lesser degree than truncation of the WD40 domain. In
addition, RAD51C mutants originally identiﬁed in individuals with
breast/ovarian cancer or FA8,38 also diminish the complex of HR
proteins. Together, our results suggest that PALB2, RAD51C and
BRCA2 directly cooperate in a network of proteins that mediate
HR, and which may thereby maintain genomic stability.
Interestingly, disruption of this network is genetically linked to
three distinct diseases: breast cancer, ovarian cancer and FA.
RESULTS
To better understand the function of RAD51C in DNA repair and
the maintenance of genomic stability, we utilized mass spectro-
metry to identify proteins that co-puriﬁed with His6-FLAG-RAD51C
(HF-RAD51C) from untreated cells (Figure 1a). As expected,
peptides for each of the RAD51 paralogs and for RAD51 were
detected by mass spectrometry. PALB2 and BRCA2 were the only
other proteins detected that were not present in mock protein
puriﬁcations. Further, these same proteins were also identiﬁed
following treatment with MMC (data not shown). Interactions with
PALB2 and BRCA2 were veriﬁed by co-immunoprecipitation with
epitope-tagged RAD51C (Figure 1b). As conﬁrmation, we also
demonstrated the reciprocal co-immunoprecipitation of RAD51C
with PALB2 (Figure 1c).
As evidence that PALB2, BRCA2, RAD51C and RAD51 form a
protein complex together, we ﬁrst immunodepleted RAD51 from
extracts of HeLa cells that expressed HF-RAD51C (Figure 1d). While
immunodepletion of RAD51 did not have a noticeable effect on
the levels of BRCA2, PALB2 or RAD51C that remained in the
extract, less PALB2, BRCA2 and RAD51 subsequently co-immuno-
precipitated with HF-RAD51C from these extracts. These results
suggest that RAD51 and RAD51C form a complex together with
PALB2 and BRCA2.
While both RAD51 and RAD51C are minor components of the
PALB2 complex(es), BRCA2 is a more abundant component
(Supplementary Figure 1). Another RAD51 paralog, XRCC3, is also
a minor component of the PALB2 complex (Figure 1c and
Supplementary Figure 1).
To better deﬁne the interaction of RAD51C with PALB2, we
compared immunoprecipitates of full-length PALB2 to a version
truncated in the middle of the protein (Y551X) (diagramed in
Figure 2a). This mutant was ﬁrst identiﬁed in EUFA1341 cells from
a FA patient.13 RAD51C, as well as BRCA2 and RAD51,
co-immunoprecipitated with full-length Flag-HA-PALB2 from
EUFA1341 cells (Figure 2b). Strikingly, however, neither RAD51C
nor BRCA2 interacted with Flag-HA–PALB2–Y551X. This truncation
mutant of PALB2 was also largely deﬁcient for interaction with
RAD51.
RAD51D is a component of the RAD51B–RAD51C–RAD51D–
XRCC2 complex of RAD51 paralogs.34 RAD51D did not associate
with the PALB2–BRCA2–RAD51C–RAD51 complex described
above (Figure 2b). This demonstrates that these two protein
complexes can be clearly distinguished.
The most prominent structural feature of the C-terminal half of
PALB2 is a WD40 domain from amino acids 853–1186. We utilized
PALB2DC (diagramed in Figure 2a), which we have described
previously,15 to determine whether RAD51C speciﬁcally interacts
with the WD40 domain of PALB2. PALB2DC is truncated following
amino acid P1097 and therefore lacks blades 5–7 of the PALB2
WD40 structure.39 PALB2DC was completely deﬁcient for
interaction with RAD51C, RAD51 and BRCA2 (Figure 2c),
suggesting that RAD51C and these other proteins interact with
the WD40 domain of PALB2.
Next, we expressed and isolated fusion proteins containing
RAD51C or the PALB2 WD40 domain from bacteria. Using this
system, we demonstrate that RAD51C bound directly to the WD40
domain of PALB2 (Figure 2d).
Figure 1. RAD51C interacts with PALB2 and BRCA2. (a) Silver-stained
gel indicating components of a RAD51C complex identified by mass
spectrometry following immunopurification from HeLa S3 cells.
RAD51C was expressed with an N-terminal His6-Flag (HF) epitope
tag. The gel was cut into four sections as indicated (left) and mass
spectrometry was performed on each piece. The number of unique
peptides identified, following subtraction of common peptides
isolated from a mock-purified control, is shown in parentheses.
(b) Immunoblot demonstrating that PALB2 and BRCA2 co-immuno-
precipitate with HF-RAD51C. (c) Immunoblot demonstrating that
RAD51C and XRCC3 co-immunoprecipitate with HF-PALB2.
(b–c) Immunoprecipitates were prepared using M2 anti-Flag beads
and extracts from HeLa (b) and EUFA1341 cells complemented with
HF-PALB2 (c). (d) PALB2, BRCA2, RAD51C and RAD51 form a protein
complex, as determined by depletion of a complex that could be
immunoprecipitated with HF-RAD51C after prior immunodepletion
of RAD51. HeLa cells were first incubated with anti-RAD51 or normal
rabbit (Cont.) antisera. Supernatants were then incubated with anti-
M2 agarose to immunoprecipitate HF-RAD51C and were immuno-
blotted with the indicated antibodies. (b–d) Immunoprecipitates
represent 200-fold the levels loaded for Input lanes. The positions of
HF-RAD51C and endogenous RAD51C or RAD51 are indicated by
arrowheads.
RAD51C interacts with PALB2
J-Y Park et al
4804
Oncogene (2014) 4803 – 4812 & 2014 Macmillan Publishers Limited
Truncation of the PALB2 WD40 domain completely abrogates
interactions with BRCA2, RAD51C and RAD51 (Figure 2c). Thus, as
an alternative that might yield more insight into the interactions
of BRCA2, RAD51C and RAD51 with PALB2, we analyzed the
effects of missense mutants/variants of PALB2 identiﬁed in a
German population of breast cancer patients.21 While missense
mutants have been identiﬁed in other studies,21–31 our study
was not intended to be exhaustive but instead focused on
selected mutants/variants of the PALB2 WD40 domain that
were predicted to potentially be disease-causing. While the
T1030I and L1143P mutants were only found in cancer patients,
the L939W variant was found at a lower frequency in controls than
in breast cancer families21 and has also been linked to breast
cancer in other studies.22,24,28 First, we examined the positions of
the three different missense mutations in the crystal structure of
the PALB2 WD40 domain.39 L939W, T1030I and L1143P are
present within blade 2, between blades 4 and 5 and between
blades 5 and 6, respectively, and therefore potentially identify
three independent binding surfaces on the PALB2 WD40
b-propeller structure (Figure 3a). This result is consistent with a
potential role for the PALB2 WD40 domain in scaffolding a
complex of HR and FA proteins, including RAD51C.
We also modeled each mutant/variant based upon the structure
of the PALB2 WD40 domain (Figures 3b–d). The L939 and L1143
residues are present on the surface of the WD40 domain structure
and are therefore likely involved in protein–protein interactions.
L939W, in particular, represents a change to a more bulky residue
that may thereby perturb potential interactions. In contrast, the
T1030I mutation likely disrupts hydrogen bonds between the
hydroxyl group of threonine 1030 and the carboxylic and amide
groups, respectively, of Glu1011 and Met1032. This mutation likely
perturbs the pocket formed by amino acids Pro1009, Glu1011,
Ile1013, Asn1034 and Lys1048 and is therefore predicted to be
unstable.
Next, we tested the effects of the L939W, T1030I and L1143P
PALB2 alterations on in vitro interactions with various HR-
associated proteins (Figure 4). Examples of a representative
experiment, performed with proteins isolated following expres-
sion in bacteria, are shown in Figure 4a. Although none of the
PALB2 mutations completely abrogated the interaction of its
WD40 element with the HR proteins, the L939W variant showed a
stronger disruption of direct binding to BRCA2 and the L1143P
mutant protein had a weaker effect on the interaction with BRCA2.
Both differences were reproducible and statistically signiﬁcant in
three independent experiments (Figure 4b). The T1030I mutant
did not show any decrease in the interaction with BRCA2.
In contrast, RAD51C and RAD51 displayed patterns of interac-
tion with each PALB2 mutant that were distinct from BRCA2 and
which were distinct from each other (Figure 4). The L939W mutant
had no effect on direct binding of the PALB2 WD40 domain by
RAD51C, but the T1030I variant, and especially the L1143P PALB2
variant, were associated with a statistically signiﬁcant decrease in
the interaction with RAD51C. In contrast, RAD51 showed a
signiﬁcant but minor decrease in binding to the L1143P mutant,
as compared to binding to the wild-type PALB2 WD40 domain.
RAD51 displayed even less binding to the L939W mutant and
especially the T1030I mutant.
The RAD51 paralog XRCC3 also directly bound to the PALB2
WD40 domain and had a pattern of binding to the mutants that
resembled that of BRCA2, but which was clearly distinct from that
of RAD51C (Figure 4). This suggests that RAD51C and XRCC3
independently interact with PALB2.
Together, results with missense mutants of PALB2, shown in
Figures 3 and 4, appear to identify three distinct surfaces on the
PALB2 WD40 b-propeller structure that are involved in binding
RAD51C, RAD51, and BRCA2 and XRCC3. Importantly, the distinct
patterns of binding of RAD51C, RAD51 and BRCA2 to these PALB2
missense mutants also suggests that each HR protein may directly
Figure 2. RAD51C directly binds to the WD40 domain of PALB2. (a) Schematic diagram of PALB2 and selected mutants. Hatched boxes indicate
WD40 repeats of PALB2. (b) Wild-type PALB2 and the Y551X truncation mutant containing N-terminal Flag and HA epitope tags were
transiently transfected into 293T cells. Immunoprecipitates represent 500-fold the levels loaded for Input lanes. (c) Cell lysates were prepared
from EUFA1341 cells reconstituted with wild-type PALB2 or the DC mutant truncated after P1097. The position of RAD51C is indicated by an
arrowhead. (b–c) Cell lysates were immmunoprecipitated with a-Flag beads, followed by immunoblotting with the indicated antibodies.
(d) Analysis of direct binding using bacterially-expressed MBP alone or MBP fused to the WD40 domain of PALB2 (amino acids 859–1186).
Bacterially expressed His6 alone, or fused to RAD51C, was incubated with MBP or MBP-PALB2 immobilized on maltose beads. Bound RAD51C
was detected by immunoblotting with anti-His antibodies following elution.
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bind to the PALB2 WD40 domain in an independent manner. The
above results support the possibility that the PALB2 WD40 domain
scaffolds a complex of HR proteins.
Given that RAD51C and XRCC3 can form a complex together,34
we tested whether the presence of PALB2 inﬂuences the
association of these proteins (Supplementary Figure 2).
Co-immunoprecipitation of RAD51C with XRCC3 was clearly
increased in cells with a deﬁciency for PALB2. This suggests that
formation of the PALB2 complex with RAD51C and/or XRCC3 may
compete with the RAD51C–XRCC3 complex.
To test their function in DNA repair, we then expressed the
three breast cancer-associated mutants of PALB2, along with
N-terminal Flag-HA epitope tags, in PALB2-deﬁcient EUFA1341
cells derived from a FA patient.13 While the L939W and L1143P
mutants expressed at similar levels as the wild-type protein, the
T1030I mutant was present at decreased levels in multiple
experiments (Figure 5a). We hypothesized that the T1030I mutant
was unstable, as predicted in Figure 3d. To further test this
possibility, we treated cells containing wild-type PALB2 or the
T1030I mutant with cycloheximide to inhibit new protein
synthesis (Figure 5b). The turnover of the mutant was more rapid
than that of the wild-type protein. Further, treatment with MG132
more modestly increased the levels of wild-type PALB2 but
restored the T1030I mutant to near the levels of wild-type protein
(Figure 5c). This suggests that the T1030I mutant of PALB2 was
degraded in a proteasome-dependent manner. Quantiﬁcation of
these results is shown in Figures 5d and e. The levels of mRNA for
each form of PALB2 were similar, however (Figure 5f). Together,
our results demonstrate that one way in which missense
mutations of the PALB2 WD40 domain may act in breast cancer
is by decreasing the stability of the encoded protein.
Unlike PALB2-T1030I protein, the L939W and L1143P mutants
appeared to be stably expressed in EUFA1341 cells (Figure 5a). To
measure the effects of the L939W and L1143P mutants/variants of
PALB2 on DNA double-strand break (DSB)-initiated HR, we
expressed each form in U2OS-DR cells that contained a GFP
reporter for HR40 and depeted endogenous PALB2 with a siRNA
directed against its 30-UTR. Each mutant displayed modest but
statistically signiﬁcant decreases in DSB-initiated HR that were
intermediate to that of cells which contained the empty vector
alone and which were depleted of endogenous PALB2 (Figure 6a).
We also tested whether the L939W and L1143P mutants of
PALB2 had any effect on RAD51 foci. We depleted endogenous
PALB2 in U2OS-DR cells that expressed PALB2-WT or either
mutant, as described above. The L1143P mutant displayed a
modest but statistically signiﬁcant decrease in the assembly of
RAD51 foci (Figure 6b), consistent with the modest but signiﬁcant
decrease in DSB-HR that is associated with this mutant.
As an additional measure of the importance of altered
interactions between the PALB2, BRCA2 and RAD51C proteins,
we tested resistance of EUFA1341 cells stably reconstituted with
the L939W and L1143P mutants/variants of PALB2 to ionizing
radiation (IR) (Figure 6c). A role for PALB2 in promoting resistance
to IR has not been reported previously. Interestingly, the L939W
and L1143P PALB2 mutants showed a moderate but signiﬁcant
increase in sensitivity to IR when compared with cells that were
isogenically corrected with wild-type PALB2.
Consistent with our ﬁndings of compromised DNA repair, the
L939W and L1143P mutants of PALB2 showed altered binding to
HR proteins in EUFA1341 cells (Figure 6d). Quantiﬁcation is shown
in Figure 6e. The interactions of BRCA2 and RAD51C with PALB2-
L1143P were statistically lower than those with PALB2-WT.
Although not statistically different from binding to PALB2-WT,
PALB2-L939W showed trends of increased binding to BRCA2 and
decreased binding to RAD51C.
Finally, we also tested RAD51C mutants for perturbation of the
complex with PALB2 and BRCA2. The L138F and D159N mutants
were identiﬁed in breast/ovarian cancer patients,8 while the
R258H mutant was identiﬁed in a FA patient.38 Each mutant was
previously demonstrated to be functionally impaired in DNA
Figure 3. Analysis of the positions and potential effects of breast cancer mutations in the PALB2 WD40 domain. (a) A ribbon diagram of the
WD40 domain of PALB2 is shown in gray (PDB ID 3EU7_ENREF_3639). The blades are numbered 1–7 and colored light gray to dark gray. The
missense mutations/variants (L939, T1030 and L1143) found in breast cancer patients are shown in stick representation and in pink. (b–c)
Surface representation of the region of PALB2 centered on Leu939 and Leu1143, respectively, colored in pink showing how both hydrophobic
residues are solvent exposed. (d) Details of residues surrounding T1030 of blade 4. Residues E1011 and M1032, which make hydrogen bonds
with the hydroxyl group of T1030, are highlighted. The figure was prepared with Pymol (http://www.pymol.org/).
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repair-related assays.8,38,41 As shown for a representative
experiment, L138F, D159N and R258H all displayed decreased
binding to BRCA2, and to a lesser degree to PALB2 and RAD51,
when expressed transiently in 293T cells (Figure 7). Thus, taken
together with Figures 4 and 6, mutations of either PALB2 or
RAD51C, found in breast/ovarian cancer or FA, perturb the
function of a complex of HR proteins that includes PALB2,
RAD51C and BRCA2.
DISCUSSION
Here, we demonstrate that the RAD51C protein interacts with, and
can directly bind, PALB2. We term this complex, which also
includes RAD51, BRCA2 and XRCC3, the ‘HR complex’. Our results
suggest that these proteins interact and function in a common
pathway of DNA repair by HR. This is particularly interesting given
that PALB2, BRCA2 and RAD51C are all breast/ovarian cancer
susceptibility (BRCA) genes,8–12,42 as well as FA genes.13,38,43,44
Notably, FA is associated with a predisposition to cancer.36 Thus,
together, our ﬁndings that patient-derived mutations of either
RAD51C or the PALB2 WD40 domain disrupt the HR complex
suggest the importance of this complex in preventing cancer.
The PALB2 WD40 domain coordinates a protein complex that
contains both RAD51C and BRCA2
While the role of PALB2 in recruiting BRCA2 to sites of DNA
damage has already been established,13,15,17 RAD51C was only
known to associate with other RAD51 paralogs, in two different
complexes,34 and with RAD18.35 Thus, we demonstrate a novel
protein complex that yields insight into the function of PALB2,
RAD51C and BRCA2 as tumor suppressors and FA proteins.
By showing that RAD51C and BRCA2, as well as RAD51, all
directly bind to the WD40 domain of PALB2, we propose that a
key function of PALB2 is to individually bind multiple proteins that
have an essential role in DSB-initiated HR.4,33,45 The role of the
PALB2 WD40 domain in binding these HR proteins is supported by
the ﬁnding that three different breast cancer-associated missense
mutants/variants of PALB2, L939W, T1030I and L1143P, have
distinct patterns of altered binding to BRCA2, RAD51C and RAD51
in vitro. In fact, the WD40 domain could scaffold a complex that
contains these HR proteins. Consistent with this possibility,
previous work has shown that WD40 domains can coordinate
simultaneous interactions with multiple proteins.46
We ﬁnd that the PALB2-L1143P mutant is associated with a
moderate but signiﬁcant decrease in RAD51 foci after exposure to IR.
Figure 4. Different patterns of in vitro binding of RAD51C, BRCA2, RAD51 and XRCC3 to disease-associated missense mutants of PALB2 suggest
that the PALB2 WD40 domain may scaffold these proteins into a complex. (a) A representative in vitro binding experiment. MBP alone, or MBP-
fused to the wild-type PALB2 WD40 domain or to different breast cancer-associated mutants/variants of this domain, was expressed in
bacteria, purified and immobilized on maltose beads. Isolated MBP-WD40 proteins or MBP alone are shown as ‘Inputs’. A GST-tagged BRCA2
fragment (amino acids 1–75) or His-tagged RAD51C, RAD51 or XRCC3 were purified from bacteria and incubated with the purified MBP fusion
proteins. Proteins present in the MBP fusion protein pull-down were detected with anti-GST or Anti-His antibodies, as appropriate. GST alone
served as a negative control for GST-BRCA2, while His alone served as a negative control for His-fusion to RAD51C, RAD51 or XRCC3. (b) A
graph is shown with quantification of binding from three independent experiments. Values for each HR protein were determined by
densitometry and adjusted relative to the levels of each form of PALB2 in the Input lanes and are shown normalized to the amounts that
immunoprecipitated with the wild-type PALB2 WD40 domain. The mean and standard deviation are shown for each value (*Po0.05;
**Po0.01).
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In contrast, this mutant results in a modest but signiﬁcant increase in
the formation of BRCA2 foci (Supplementary Figure 3). It is possible
that by binding to PALB2, RAD51C normally leads to a concomitant
release of BRCA2 and recruitment of RAD51. This might explain the
increased levels of BRCA2 foci and decreased RAD51 foci observed
in cells reconstituted with the PALB2-L1143P mutant. This process
could involve the DNA-binding activity of RAD51C47 and/or a
change in the composition of the complex with PALB2. The PALB2-
L1143P mutant could have indirect effects on RAD51, because it had
altered interactions with RAD51C and BRCA2 but not RAD51 both
in vitro (Figure 4) and in cells (Figure 6). We expect that decreased
recruitment of RAD51, despite increased levels of BRCA2 foci,
underlies the signiﬁcant decreases in HR and resistance to IR that are
associated with the PALB2-L1143P mutant.
Contrasting reports have suggested that RAD51C and XRCC3
function either before or after RAD51 foci formation33,38,48,49 in
various cell types, including human cells, following exposure to
DNA damage. While the PALB2-L1143P mutant would appear to
have some defect before RAD51 foci formation, this does not
preclude an additional function afterwards. The interaction of
RAD51C with PALB2 could have a role in promoting RAD51 foci
formation, because the PALB2-L1143P mutant includes a defect in
this interaction.
As added support for the effects of missense mutations of the
PALB2 WD40 domain on DNA repair, the L939W variant but not
L1143P is associated with an intermediate sensitivity to a PARP
inhibitor (Supplementary Figure 4). As both mutants are
associated with increased sensitivity to IR, this could reﬂect
different patterns of interactions of each mutant with HR proteins
(Figure 4).
RAD51 is unlikely to be required for the interactions of BRCA2 or
RAD51C with the WD40 domain of PALB2. First, both BRCA2 and
RAD51C directly, and thus potentially independently, bind the
PALB2 WD40 domain (Figure 4). Second, siRNA-mediated deple-
tion of RAD51 decreased the levels of RAD51 but not those of
PALB2 or BRCA2, which immunoprecipitated with RAD51C
(Supplementary Figure 5).
While the PALB2–BRCA2–RAD51C–RAD51 complex appears
to be independent of the previously described RAD51B-C-D–
XRCC2 complex,34 another RAD51 paralog, XRCC3, appears
to interact with this PALB2 complex (Figures 1c and 4). This is
the third reported complex with multiple RAD51 paralogs, but
the ﬁrst that includes non-paralog proteins. Given that the
L939W and L1143P mutants of PALB2 have altered interactions
with RAD51C, XRCC3 and BRCA2, and RAD51, and are defective
for DNA repair, these RAD51 paralogs would appear to have a
function in this PALB2 complex. While RAD51C-XRCC3 has been
reported to have a Holliday junction resolvase activity in vitro,50 it
is currently unclear what function, if any, this complex by itself
has in intact cells.
A protein complex has been reported that includes FANCG,
FANCD2, BRCA2 and XRCC3.51 Given that we describe a PALB2
Figure 5. The breast cancer-associated T1030I mutant of PALB2 is unstable. (a) Wild-type PALB2 or the L939W, T1030I and L1143P mutants/
variants were retrovirally expressed in EUFA1341 cells along with a N-terminal Flag-HA epitope tag. The level of each protein was determined
by immunoblotting with a-HA antibodies. Actin was used as a loading control. (b) To examine relative rates of turnover, new protein synthesis
was inhibited in EUFA1341 cells reconstituted with Flag-HA-tagged wild-type PALB2 or with the T1030I mutant by treating with 40 mg/ml
cycloheximide. Cell lysates were prepared at the indicated time points. (c) EUFA1341 cells reconstituted with wild-type PALB2 or the T1030I
mutant were treated with 10 mM MG132 and harvested at the indicated time points. (d–e) Quantification of the levels of wild-type PALB2 or the
T1030I mutant following treatment with cycloheximide (d) or MG132 (e) at various time points, as determined by densitometry of
immunoblots. Results for each protein were normalized to the values at 0 h (d) or 2 h (e) of treatment. (f ) Levels of mRNA of wild-type or
mutant PALB2 in reconstituted EUFA1341 cells were analyzed by RT–PCR. Primers that detected Flag-HA-tagged PALB2 but not endogenous
PALB2 were utilized. GAPDH was used as a control for the levels of an unrelated endogenous protein.
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complex that contains BRCA2 and XRCC3, these complexes may
be related. Future work will be required to examine this potential
relationship.
Comparison of the effects of truncation mutants of the PALB2
WD40 domain to those of missense mutants
Mutants of PALB2 found in breast cancer and FA patients that
result in a non-functional truncated protein, due to partial removal
or absence of the WD40 domain, are completely deﬁcient for DSB-
initiated HR.10,12,13 These truncations abrogate binding to BRCA2
and we report here that such large-scale truncations also eliminate
binding to RAD51C and RAD51 (Figure 2c), and thereby fully
disrupt the HR complex.
More recently, missense mutations of PALB2 have been identiﬁed
in breast/ovarian cancer patients and are also present in FA
patients.10,11,13,21–31 As these mutants, in general, are not clearly
pathogenic, it is more difﬁcult to predict any clinical outcome,
especially in heterozygous carriers. Here, we have performed the
ﬁrst functional characterization of such PALB2 missense mutants/
variants. In contrast to truncating mutants, selected missense
mutants of the WD40 domain are found to be associated with
partial but incomplete disruption of the HR complex. Corres-
pondingly, DSB-initiated HR is only partially compromised.
The breast cancer-associated L939W and L1143P mutants/
variants of PALB2 are linked to modest but signiﬁcantly-decreased
DSB-initiated HR efﬁciencies and increased IR sensitivities
(Figure 6). We therefore predict that missense mutants of PALB2
Figure 6. The L939W and L1143P mutants of the PALB2 WD40 domain are associated with defective DSB-initiated HR and with increased
sensitivity to IR. (a) Gene conversion assays were performed in U2OS-DR cells stably expressing wild-type PALB2, or the L939W or L1143P
mutants, and depleted of endogenous PALB2 using a siRNA directed against its 30-UTR. GFP-positive cells were quantified by flow cytometry.
Each value represents the average of three independent experiments performed in duplicate. The data shown are the mean and standard
deviation of three independent replicates (*Po0.05; **Po0.01). (b) The percentage of cells with RAD51 foci at 16 h after exposure to 10Gy IR.
U2OS-DR cells were stably reconstituted with the different forms of PALB2, as indicated, and endogenous PALB2 was depleted as described
above. Each value represents the mean and standard deviation of three counts ofX150 cells each with three or more RAD51 foci (*Po0.05).
(c) An IR colony assay was performed in EUFA1341 cells reconstituted with wild-type PALB2, the L939W or L1143P mutants, or with vector
alone. Cells were treated with the indicated doses of IR. Differences for EUFA1341 cells reconstituted with the vector or with either mutant, as
compared with cells corrected with WT PALB2, were statistically significant (Po0.05) at doses of IR ranging from 1–8Gy. (d–e) Wild-type PALB2,
the L939W or L1143P mutants, or the vector alone were stably expressed in EUFA1341 cells along with a N-terminal Flag-HA epitope tag.
Levels of associated HR proteins in extracts (Input), or in immunoprecipitates (IP) prepared using a-Flag M2 agarose beads, are shown in (d).
These results are representative of two independent experiments. The position of RAD51C is indicated by an arrowhead. Immunoprecipitates
represent 200-fold the levels loaded for Input lanes. Quantification of the levels of BRCA2, RAD51C or RAD51 that immunoprecipitated with
the WT, L939W or L1143P forms of PALB2 in two independent experiments (e). Levels of immunoprecipitating protein were normalized to the
input for each form of PALB2 and each interacting protein. The average±s.d. are shown relative to the values for PALB2-WT (which was set to
100%). Statistical significance: *Po0.05; **Po0.01.
RAD51C interacts with PALB2
J-Y Park et al
4809
& 2014 Macmillan Publishers Limited Oncogene (2014) 4803 – 4812
may confer lower levels of genomic instability, and thus a lower
risk of cancer, than truncation mutants. Notably, our repair-related
assays indicate that the L939W variant identiﬁed in various
studies,21,22,24,28 which generally occurs more frequently in breast
cancer patients than in healthy individuals, may be pathogenic.
Importantly, our study establishes assays for the functional
characterization of other missense mutants/variants of PALB2 in
the future.
Results obtained with the L939W, T1030I and L1143P mutants/
variants of PALB2 suggest that there are at least two different
mechanisms by which missense mutants of the PALB2 WD40
domain may lead to increased genomic instability in breast
cancer. First, we ﬁnd that the T1030I mutant is unstable when
expressed in human cells. Decreased levels of PALB2-T1030I due
to instability are therefore expected to diminish its function in HR.
A second means by which mutants of the PALB2 WD40 domain
may lead to increased genomic instability is by altered binding to
HR proteins, as illustrated by the L939W and L1143P mutants/
variants. The L1143P mutant signiﬁcantly decreased binding to
RAD51C and BRCA2, both in vitro and in human cells.
PALB2, BRCA2 and RAD51C are linked to breast/ovarian cancer and
to Fanconi anemia
FA is an inherited chromosome instability syndrome clinically
characterized by bone marrow failure, congenital anomalies and a
predisposition to leukemia and various solid tumors.36 Eight of the
16 identiﬁed FA proteins (FANCA/B/C/E/F/G/L/M) form a core
complex required for the monoubiquitination of FANCD2 and
FANCI.36,37 Other FA proteins, including PALB2, BRCA2 and
RAD51C, are not required for the monoubiquitination of
FANCD2 or FANCI, and are therefore believed to function
downstream of FANCD2.13,38,43,44 Interestingly, BRCA2,52
RAD51C33 and, as we show here, PALB2, are required for cellular
resistance to IR, unlike upstream FA proteins that lead to the
monoubiquitination of FANCD2 and FANCI. Further, PALB2,
BRCA2, and RAD51C are associated with inherited breast cancer,
whereas upstream FA pathway proteins are not.53 Thus, a more
prominent role in DSB repair and in cellular resistance to IR may
underlie the shared association of the PALB2, RAD51C and BRCA2
subset of FA genes with breast cancer. Consistent with this
possibility, the products of other breast cancer susceptibility
genes, including BRCA1, BRIP1, ATM, CHEK2, NBS1 and RAD50,2 are
also involved in mediating the repair of DSBs induced by IR.
In conclusion, we have identiﬁed a novel complex of HR and
BRCA proteins. Importantly, our results yield insight into the
function of PALB2 as a tumor suppressor by demonstrating that its
WD40 domain may act to coordinate this complex, which contains
two other tumor suppressor proteins: BRCA2 and RAD51C. Finally,
the function of this complex in DNA repair may be the basis for
the common association of the products of the PALB2, RAD51C
and BRCA2 genes with three distinct diseases: breast cancer,
ovarian cancer and FA.
MATERIALS AND METHODS
Cell culture
HeLa S3, 293T and U2OS-DR cell lines, and EUFA1341 cells reconstituted
with different forms of PALB2, were cultured and irradiated as described
previously.15 Stock solutions of cycloheximide (10mg/ml in H2O; Sigma),
MG132 (10mM in DMSO; Calbiochem) and Olaparib (5mg/ml in DMSO;
Selleck Chemicals) were kept at  20 1C.
Antibodies
Mouse anti-RAD51C (2H11) and rabbit anti-XRCC3 antibodies were
purchased from Novus. Rabbit anti-RAD51 (H92) and mouse anti-His (H8)
antibodies were purchased from Santa Cruz. Mouse anti-RAD51D (5B3)
antibody was obtained from Chemicon. Anti-HA, anti-maltose-binding
protein (anti-MBP), anti-Glutatione S-transferase (anti-GST), anti-b actin,
anti-PALB2 antibodies15 and anti-BRCA2 antibodies54 were described
previously.
Immunoﬂuorescence microscopy
Cells were ﬁxed and processed with antibodies as described previously.15
Cloning and mutagenesis
Human RAD51C cDNA was purchased from Open Biosystems. RAD51C with
N-terminal Flag-HA or His-Flag epitope tags were generated and
subcloned into pcDNA3.1. Alternatively, RAD51C was cloned into the
pMIEG3 retroviral vector with an N-terminal His6-Flag epitope tag.
55 PALB2
mutants (L939W, T1030I and L1143P) were generated as described
previously.15 To generate fusion proteins for in vitro studies, the PALB2
WD40 domain (amino acids 859–1186), RAD51 or RAD51C were cloned
into pMAL-c2X (NEB) with N-terminal MBP. Alternatively, RAD51C was
cloned into pET28b (Novagen) with C-terminal Histidine (His). An
N-terminal fragment of BRCA2 (1–75 a.a) was cloned into pGEX4T-1,
which contained N-terminal GST.
Expression and puriﬁcation of recombinant proteins
Fusion proteins were expressed in bacteria (4 h at 30 1C with 0.3mM
isopropyl b-thiogalactopyranoside). Recombinant proteins were puriﬁed
using amylose resins (NEB) for MBP, glutathione sepharose 4B beads (GE
healthcare) for GST and Talon metal afﬁnity resins (Clontech) for His,
according to the manufacturers’ instructions.
In vitro GST and MBP pull-downs
GST and MBP-tagged proteins (5mg) were bound to glutathione beads and
amylose resins, respectively, and mixed with 5 mg of each puriﬁed target
protein in binding buffer (10mM Tris pH 7.4, 75mM NaCl, 0.5mM EDTA,
0.025% Tween-20, 1mM DTT and 0.5mg/ml BSA) including 0.5mM PMSF
and 1 protease inhibitor cocktail and incubated overnight at 4 1C. Beads
were then washed and bound proteins eluted.
Transfection and viral transduction
Retroviral transduction with pMIEG3-RAD51C, or pMMP-PALB2 wild-type
and its mutants with a N-terminal Flag-HA tag, was performed as described
previously.15,55 Cells transduced with pMMP-PALB2 or its mutants were
selected with 0.5mg/ml puromycin for 6 days after the last infection.
Identiﬁcation of RAD51C-interacting proteins by mass
spectrometry
RAD51C complexes were puriﬁed from HeLa S3 cells retrovirally
transduced with His6-FLAG-tagged RAD51C as described previously.
56
The immunopuriﬁed complex was analyzed by mass spectrometry.
Figure 7. Disease-associated mutants of RAD51C have decreased
interactions with BRCA2 and PALB2. Wild-type RAD51C, the L138F
and D159N mutants found in breast cancer patients, or the R258H
mutant found in an FA patient, were transiently expressed in 293T
cells along with an N-terminal Flag-HA epitope tag. The levels of
protein in extracts (Input) or in immunoprecipitates prepared using
a-Flag M2 agarose beads (IP) were determined by immunoblotting
with the indicated antibodies. Immunoprecipitates represent 500-
fold the levels loaded for Input lanes.
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Immunoprecipitation
Cell pellets were lysed in 420 NETN buffer as described previously.15
Immunoprecipitations were performed with anti-Flag M2 Afﬁnity Gel
(Sigma) or speciﬁed antibodies as described previously.15
RT-PCR analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. Synthesis of cDNAs from RNA with the
Advantage RT for PCR Kit (Clontech) was carried out by PCR-ampliﬁcation
using the following primers: forward: 50-GTGATGCTGTACTGTTGTCTTCCT-30 ;
reverse: 50-CGACTTGTCATCGTCGTCCTTG-30 .
Assay of DNA DSB-initiated HR
U2OS-DR cells with an integrated GFP reporter and containing PALB2 or its
mutants were assayed as described previously.15
IR colony and PARP inhibitor sensitivity assays
EUFA1341 cells reconstituted with wild-type PALB2 or its mutants were
seeded onto 6-cm dishes (2 103 cells/dish) in triplicate, and after allowing
attachment cells were irradiated. Cells were incubated for 10–12 days to
form colonies and washed with PBS. Colonies were ﬁxed with Wright–
Giemsa reagent (EMD), stained with Buffer solution Giordano (Fisher), dried
and counted manually.
To measure Olaparib sensitivity, cells were seeded into 96-well plates at
1 106 cells/well and were treated with a range of concentrations of
olaparib beginning 4 h later. Cells were incubated for 4 days and relative
survival was measured using a colorimetric assay.15
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